Expert Insights

How Real World Data is Changing the Pharmaceutical Industry

by Erin Booth, PhD, January 10, 2019
Approximately 90 percent of global pharmaceutical companies are using, or have plans to use real world data in the near future, according to a 2018 benchmarking survey from Deloitte. This coincides with an increased focus on the use of real world evidence from the U.S. Food & Drug Administration (FDA).

How to overcome project resourcing issues in the pharmaceutical industry

by Kristin Chesney, MBA and Don McLean, MBA, December 20, 2018
The pharmaceutical industry has eclipsed 4.4 million employees globally. With worldwide sales planned to increase from $860 billion in 2019 to more than $1.06 trillion by 2022, project resourcing will be even more critical than it is today.

The Ultimate Checklist for Being a Good Mentor in Pharma

by Staff writer, December 13, 2018
According to, young adults who are mentored are 130 percent more likely to hold leadership positions in the future. Strong mentors assist is building strong junior-level colleagues – especially in the pharmaceutical and biotech industries.

Medical writing: Its future, people, and processes

by Teresa Ceseña, November 29, 2018
While attending the invitation-only Medical Writing Executives Forum: Preparing for the Future of Medical Writing in Pharma and Biotech for the American Medical Writer’s Association (AMWA) in Washington, D.C., it was evident that the medical writing profession is evolving.

Flexibility, CRO growth, and real world data: A conversation with Kelly J. Hill

by Staff writer, November 16, 2018
Executives come and go, but strong leaders like Kelly J. Hill, help shape an organization and its future. As Executive Director, Global Project & Account Management at MMS, Kelly discusses how thoughtful planning, strong values, and a company focus on data showcase MMS as an emerging leader of specialized CROs in this expert Q&A.

Why Lay Summaries Matter and Their Future

by Staff writer, November 8, 2018
Plain language summaries, commonly known as lay summaries, have become increasingly important for pharmaceutical companies in recent years. However, there are many sponsors that have yet to start their pilot programs for these documents.

Teamwork, growth, and changing lives: A conversation with Michelle Gayari

by Staff writer, November 1, 2018
Many leaders say they value their people, but few may mean it as much as Michelle Gayari, Executive Director, Global Operations at MMS. In this candid conversation, Michelle leans in to the power of her teams and what it’s like being part of a stable, growing organization.

Four initiatives to combat the opioid epidemic

by Jeffrey Wiese and Julie Legakis, October 25, 2018
Opioid use in the U.S. is widespread. Last year, there were 58 opioid prescriptions filled for every 100 U.S. citizens, more than 40 percent of all U.S. opioid overdose deaths in 2016 involved a prescription according to the Centers for Disease Control and Prevention(CDC). Additionally, the U.S. opioid market is a $13 billion industry, with approximately 60 approved opioids available.


6880 Commerce Blvd.
Canton, MI 48187 USA
734.245.0310 T
734.245.0320 F

Email Us


Learn more about working with MMS

7 + 13 =

© MMS Holdings Inc. All rights reserved. Privacy Policy